Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 3
2007 2
2011 1
2012 1
2013 3
2014 1
2015 1
2019 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Dominant mutations in ORAI1 cause tubular aggregate myopathy with hypocalcemia via constitutive activation of store-operated Ca²⁺ channels.
Endo Y, Noguchi S, Hara Y, Hayashi YK, Motomura K, Miyatake S, Murakami N, Tanaka S, Yamashita S, Kizu R, Bamba M, Goto Y, Matsumoto N, Nonaka I, Nishino I. Endo Y, et al. Among authors: tanaka s. Hum Mol Genet. 2015 Feb 1;24(3):637-48. doi: 10.1093/hmg/ddu477. Epub 2014 Sep 16. Hum Mol Genet. 2015. PMID: 25227914
Possible involvement of the alpha1 isoform of 5'AMP-activated protein kinase in oxidative stress-stimulated glucose transport in skeletal muscle.
Toyoda T, Hayashi T, Miyamoto L, Yonemitsu S, Nakano M, Tanaka S, Ebihara K, Masuzaki H, Hosoda K, Inoue G, Otaka A, Sato K, Fushiki T, Nakao K. Toyoda T, et al. Among authors: tanaka s. Am J Physiol Endocrinol Metab. 2004 Jul;287(1):E166-73. doi: 10.1152/ajpendo.00487.2003. Epub 2004 Mar 16. Am J Physiol Endocrinol Metab. 2004. PMID: 15026306 Free article.
Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.
Yamazaki T, Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yokoi H, Yoshida M; Justification for Atherosclerosis Regression Treatment (JART) Investigators. Yamazaki T, et al. Int Heart J. 2013;54(1):33-9. doi: 10.1536/ihj.54.33. Int Heart J. 2013. PMID: 23428922 Free article. Clinical Trial.
Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness--Justification for Atherosclerosis Regression Treatment (JART) extension study.
Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yamazaki T, Yokoi H, Yoshida M; Justification For Atherosclerosis Regression Treatment (JART) Investigators. Nohara R, et al. Circ J. 2013;77(6):1526-33. doi: 10.1253/circj.cj-12-1149. Epub 2013 Mar 14. Circ J. 2013. PMID: 23486191 Free article. Clinical Trial.
13 results